(MENAFN – GetNews) The global drug screening market was valued at $9.1 billion in 2024 and is projected to grow to $19.5 billion by 2029, at a CAGR of 16.6%. In 2021, it was valued at $5.3 billion, expected to reach $11.6 billion by 2026, growing at a CAGR of 16.8%. This growth is driven by increasing drug and alcohol consumption and stricter testing regulations, although bans in Islamic countries and restrictions on workplace testing may hinder progress.
Major Players in Drug Screening:
- LabCorp (US)
- Quest Diagnostics (US)
- Abbott Laboratories (US)
- Thermo Fisher Scientific (US)
- Alfa Scientific Designs (US)
- OraSure Technologies (US)
- Siemens Healthineers (Germany)
- Roche (Switzerland)
- MPD Inc. (US)
- More…
Market Segmentation:
- By Product and Service
- Drug Screening Products (Analytical Instruments, Rapid Testing Devices, Consumables)
- Drug Screening Services
- By Sample Type (Urine, Breath, Oral Fluid, Hair)
- By End User (Laboratories, Workplaces, Criminal Justice, Healthcare Providers, etc.)
- By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Recent Developments:
- Aug 2021: Quest Diagnostics expanded its lab network with Select Health.
- Sept 2020: LabCorp partnered with Infirmary Health for lab services.
- May 2020: Psychemedics launched a new vaping test.
FAQs:
1. Impact of COVID-19? It has disrupted the market but the effects are expected to be short-term.
2. Key players? LabCorp, Quest Diagnostics, Abbott, and others.
3. Segment dominance? Services are expected to lead due to rising drug use and testing initiatives.
4. Fastest-growing end user? Drug Testing Laboratories.
5. Market projection? Expected to reach $11.6 billion by 2026.
Get 10% Free Customization on this Report.
Objectives:
- Define and forecast the drug screening market.
- Analyze factors affecting growth.
- Identify opportunities for stakeholders.
`
